Development and characterization of liposomal formulation of bortezomib

• Váldodahkkit: Anil K. Deshantri (Dahkki), Josbert M. Metselaar (Dahkki), Stavroula Zagkou (Dahkki), Gert Storm (Dahkki), Sanjay N. Mandhane (Dahkki), Marcel H.A.M. Fens (Dahkki), Raymond M. Schiffelers (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2019-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic...